Do analysts recommend ABC or ONT?

Oxford Nanopore Technologies has a consensus target price of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Abcam. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abcam 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Do analysts prefer ERGO or ONT?

Oxford Nanopore Technologies has a consensus target price of GBX 218.60, suggesting a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Oxford Nanopore Technologies (ONT) Competitors

GBX 114.70 +1.50 (+1.33%)

As of 12:14 PM Eastern

Compare

ONT vs. ABC, GNS, OXB, ERGO, and SLN

Should you buy Oxford Nanopore Technologies stock or one of its competitors? MarketBeat compares Oxford Nanopore Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Nanopore Technologies include Abcam (ABC), Genus (GNS), Oxford Biomedica (OXB), Ergomed (ERGO), and Silence Therapeutics (SLN). These companies are all part of the "biotechnology" industry.

How does Oxford Nanopore Technologies compare to Abcam?

Abcam (LON:ABC) and Oxford Nanopore Technologies (LON:ONT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Abcam has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -64.85%. Abcam's return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Oxford Nanopore Technologies has a consensus target price of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Abcam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Abcam's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Abcam	Neutral
Oxford Nanopore Technologies	Positive

Abcam has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	£350.40M	0.00	N/A	£0.06	N/A
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A

19.6% of Oxford Nanopore Technologies shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Abcam and Oxford Nanopore Technologies tied by winning 6 of the 12 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Genus?

Genus (LON:GNS) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Genus has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.09	£7.87M	£71.00	29.72
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A

52.9% of Genus shares are owned by institutional investors. Comparatively, 19.6% of Oxford Nanopore Technologies shares are owned by institutional investors. 0.7% of Genus shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genus currently has a consensus target price of GBX 3,216.67, suggesting a potential upside of 52.45%. Oxford Nanopore Technologies has a consensus target price of GBX 218.60, suggesting a potential upside of 90.58%. Given Oxford Nanopore Technologies' higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Genus' score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Genus	Neutral
Oxford Nanopore Technologies	Positive

Genus has a net margin of 7.07% compared to Oxford Nanopore Technologies' net margin of -64.85%. Genus' return on equity of 9.70% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Genus has a beta of 0.896, meaning that its share price is 10% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.914, meaning that its share price is 9% less volatile than the broader market.

Summary

Genus beats Oxford Nanopore Technologies on 9 of the 15 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 19.6% of Oxford Nanopore Technologies shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Oxford Biomedica currently has a consensus target price of GBX 604.32, indicating a potential upside of 0.72%. Oxford Nanopore Technologies has a consensus target price of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.30	-£143.51M	-£26.92	N/A
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A

Oxford Biomedica has a beta of 1.096, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.914, indicating that its stock price is 9% less volatile than the broader market.

In the previous week, Oxford Biomedica had 3 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Oxford Biomedica's score of 0.25 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Oxford Nanopore Technologies	Positive

Summary

Oxford Biomedica beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Ergomed?

Ergomed (LON:ERGO) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Ergomed has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£152.09M	0.00	£15M	£0.29	N/A
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A

71.1% of Ergomed shares are held by institutional investors. Comparatively, 19.6% of Oxford Nanopore Technologies shares are held by institutional investors. 18.2% of Ergomed shares are held by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Ergomed's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Ergomed	Neutral
Oxford Nanopore Technologies	Positive

Ergomed has a net margin of 9.87% compared to Oxford Nanopore Technologies' net margin of -64.85%. Ergomed's return on equity of 18.08% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ergomed	9.87%	18.08%	10.16%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Oxford Nanopore Technologies has a consensus target price of GBX 218.60, suggesting a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.914, indicating that its share price is 9% less volatile than the broader market.

Summary

Ergomed beats Oxford Nanopore Technologies on 8 of the 14 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Oxford Nanopore Technologies (LON:ONT) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

19.6% of Oxford Nanopore Technologies shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Silence Therapeutics had 1 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 1 mentions for Silence Therapeutics and 0 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 1.26 beat Silence Therapeutics' score of -0.77 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Positive
Silence Therapeutics	Negative

Silence Therapeutics has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	4.98	-£175.21M	-£15.10	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

Oxford Nanopore Technologies currently has a consensus price target of GBX 218.60, indicating a potential upside of 90.58%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silence Therapeutics has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -64.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Silence Therapeutics	N/A	N/A	N/A

Summary

Oxford Nanopore Technologies beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Oxford Nanopore Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONT vs. The Competition

Export

Metric	Oxford Nanopore Technologies	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£1.12B	£474.43M	£6.45B	£2.78B
Dividend Yield	N/A	3.86%	2.69%	6.16%
P/E Ratio	-7.60	3.12	24.92	365.72
Price / Sales	4.98	6,492.01	528.81	86,253.69
Price / Cash	4.04	13.13	44.82	27.85
Price / Book	1.71	91.17	10.79	7.92
Net Income	-£175.21M	-£96.07M	£3.56B	£5.89B
7 Day Performance	-2.43%	1.69%	1.67%	-0.87%
1 Month Performance	-11.74%	0.77%	0.43%	-0.76%
1 Year Performance	-7.72%	64.35%	32.84%	70.67%

Oxford Nanopore Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONT Oxford Nanopore Technologies	2.6475 of 5 stars	GBX 114.70 +1.3%	GBX 218.60 +90.6%	-4.9%	£1.12B	£223.90M	N/A	1,281	Positive News
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	2.4798 of 5 stars	GBX 2,216 +1.7%	GBX 3,216.67 +45.2%	+11.0%	£1.47B	£672M	31.21	480	High Trading Volume
OXB Oxford Biomedica	1.1954 of 5 stars	GBX 601 -0.5%	GBX 604.32 +0.6%	+86.3%	£727.26M	£168.74M	N/A	891	News Coverage Gap Up
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:ONT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. ABC, GNS, OXB, ERGO, and SLN

How does Oxford Nanopore Technologies compare to Abcam?

Summary

How does Oxford Nanopore Technologies compare to Genus?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Summary

How does Oxford Nanopore Technologies compare to Ergomed?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. ABC, GNS, OXB, ERGO, and SLN

How does Oxford Nanopore Technologies compare to Abcam?

Is ABC or ONT more profitable?

Do analysts recommend ABC or ONT?

Does the media favor ABC or ONT?

Which has better earnings & valuation, ABC or ONT?

Do institutionals & insiders believe in ABC or ONT?

Summary

How does Oxford Nanopore Technologies compare to Genus?

Which has better earnings and valuation, GNS or ONT?

Do institutionals and insiders have more ownership in GNS or ONT?

Do analysts rate GNS or ONT?

Does the media prefer GNS or ONT?

Is GNS or ONT more profitable?

Which has more volatility & risk, GNS or ONT?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Do institutionals and insiders have more ownership in OXB or ONT?

Is OXB or ONT more profitable?

Do analysts prefer OXB or ONT?

Which has preferable earnings and valuation, OXB or ONT?

Which has more risk and volatility, OXB or ONT?

Does the media prefer OXB or ONT?

Summary

How does Oxford Nanopore Technologies compare to Ergomed?

Which has stronger valuation & earnings, ERGO or ONT?

Do institutionals & insiders believe in ERGO or ONT?

Does the media prefer ERGO or ONT?

Is ERGO or ONT more profitable?

Do analysts prefer ERGO or ONT?

Which has more risk & volatility, ERGO or ONT?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Do insiders & institutionals believe in ONT or SLN?

Does the media favor ONT or SLN?

Which has higher valuation & earnings, ONT or SLN?

Do analysts recommend ONT or SLN?

Is ONT or SLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools